Transgene
Clinical-stage biotechnology company developing viral vector-based immunotherapies for cancer and infectious diseases. Core activities include individualized neoantigen therapeutic vaccine discovery and per-patient manufacturing, engineering of poxvirus-derived oncolytic and vaccine vectors, scalable cell-line-derived vector production in GMP environments, and integrated clinical and translational development supported by advanced preclinical models and computational neoantigen prioritization.
Industries
Nr. of Employees
medium (51-250)
Transgene
Illkirch-Graffenstaden, Grand Est, France
Patents
Products
TG4050
Individualized neoantigen therapeutic vaccine constructed in a viral vector platform and produced per-patient following neoantigen selection; developed for adjuvant treatment of resected solid tumors.
TG4070
Second individualized neoantigen therapeutic vaccine candidate derived from the same discovery platform, evaluated in early-stage clinical development and designed for combination with immune checkpoint inhibitors.
Oncolytic vaccinia platform candidates
Armed oncolytic vaccinia candidates engineered to express immunostimulatory transgenes, antibody transgenes or prodrug-activating enzymes for intratumoral or systemic delivery in solid tumors.
BT-001
Multifunctional oncolytic vaccinia virus engineered to express a Treg-depleting anti-CTLA4 antibody transgene and GM-CSF cytokine transgene; designed to replicate in tumors with local payload expression and evaluated as single agent and in combination with systemic anti-PD-1 therapy in Phase I/IIa studies.
Cell-line-derived vaccinia vaccine candidates
Vaccinia-based prophylactic and therapeutic vaccine candidates produced using scalable cell-line-derived production processes for infectious disease and oncology indications.
TG4050
Individualized neoantigen therapeutic vaccine constructed in a viral vector platform and produced per-patient following neoantigen selection; developed for adjuvant treatment of resected solid tumors.
TG4070
Second individualized neoantigen therapeutic vaccine candidate derived from the same discovery platform, evaluated in early-stage clinical development and designed for combination with immune checkpoint inhibitors.
Oncolytic vaccinia platform candidates
Armed oncolytic vaccinia candidates engineered to express immunostimulatory transgenes, antibody transgenes or prodrug-activating enzymes for intratumoral or systemic delivery in solid tumors.
BT-001
Multifunctional oncolytic vaccinia virus engineered to express a Treg-depleting anti-CTLA4 antibody transgene and GM-CSF cytokine transgene; designed to replicate in tumors with local payload expression and evaluated as single agent and in combination with systemic anti-PD-1 therapy in Phase I/IIa studies.
Cell-line-derived vaccinia vaccine candidates
Vaccinia-based prophylactic and therapeutic vaccine candidates produced using scalable cell-line-derived production processes for infectious disease and oncology indications.
Services
Design and conduct of early-stage and larger oncology clinical trials (Phase I–III) for individualized vaccines and oncolytic viral therapies, with integrated translational endpoints.
Collaborative development agreements for computational tools, viral vector engineering, oncolytic design platforms and clinical programs, including licensing of production cell lines and option/license arrangements.
Development and use of patient-derived 3D tumoroids, organoids and cancer-on-chip models, plus translational assay development and analytical characterization to support preclinical evaluation.
Design and conduct of early-stage and larger oncology clinical trials (Phase I–III) for individualized vaccines and oncolytic viral therapies, with integrated translational endpoints.
Collaborative development agreements for computational tools, viral vector engineering, oncolytic design platforms and clinical programs, including licensing of production cell lines and option/license arrangements.
Development and use of patient-derived 3D tumoroids, organoids and cancer-on-chip models, plus translational assay development and analytical characterization to support preclinical evaluation.
Expertise Areas
- Individualized neoantigen vaccine development and per-patient manufacturing
- Oncolytic and poxvirus-derived vector engineering
- Clinical trial design and execution across Phase I–III oncology studies
- Translational immunology and immune-monitoring assay development
Key Technologies
- Poxvirus-derived vector engineering
- Oncolytic viral platforms with modular payloads
- Antibody-encoding oncolytic viral vectors
- Cytokine transgene expression from viral vectors
News & Updates
Phase I clinical and translational findings for an individualized neoantigen vaccine program, reporting three-year disease-free survival outcomes and associated immunogenicity data.
Announcement describing extension of the individualized neoantigen vaccine platform and related platform development activities.
Strategic partnership expansion and additional license agreement to access a production mammalian cell line for scalable viral vector manufacturing.
Preclinical results showing protection in infectious disease models for a vaccinia-based vaccine candidate produced using a scalable cell-line process.
Announcement of development activity and clinical evaluation plans to extend individualized neoantigen vaccine programs to non-small cell lung cancer indications.
Journal article and conference abstracts describing an oncolytic vaccinia virus encoding IL-12 and immune-modulatory antibody formats that remodel the tumor microenvironment and induce antitumoral responses.
Phase I clinical and translational findings for an individualized neoantigen vaccine program, reporting three-year disease-free survival outcomes and associated immunogenicity data.
Announcement describing extension of the individualized neoantigen vaccine platform and related platform development activities.
Strategic partnership expansion and additional license agreement to access a production mammalian cell line for scalable viral vector manufacturing.
Preclinical results showing protection in infectious disease models for a vaccinia-based vaccine candidate produced using a scalable cell-line process.
Announcement of development activity and clinical evaluation plans to extend individualized neoantigen vaccine programs to non-small cell lung cancer indications.
Journal article and conference abstracts describing an oncolytic vaccinia virus encoding IL-12 and immune-modulatory antibody formats that remodel the tumor microenvironment and induce antitumoral responses.